Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sci PharmtechTPE:4119 -0.19%75 EV-to-EBIT is 86.45 as of Aug. 21, 2026, which is 418% above its 10-year median of 16.68. GuruFocus rates TPE:4119 with a GF Score™ of 75/100 and a GF Value™ of NT$74.27 (Possible Value Trap). The stock has 10 warning signs investors should review. Among 690 Drug Manufacturers companies, Sci Pharmtech ranks worse than 92.9% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sci Pharmtech's Enterprise Value for the quarter that ended in Jun. 2026 was NT$6,331 Mil.
Sci Pharmtech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sci Pharmtech EV-to-EBIT Related Terms
Sci Pharmtech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sci Pharmtech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sci Pharmtech EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sci Pharmtech's EV-to-EBIT falls into.
Sci Pharmtech's current Enterprise Value is NT$7,227 Mil.
Sci Pharmtech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sci Pharmtech (TPE:4119) has a EV-to-EBIT of 86.45 as of Aug. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sci Pharmtech and its competitors. This is 418% above median its historical median of 16.68. According to the industry distribution chart, Sci Pharmtech ranks #641 out of 690 companies in the Drug Manufacturers industry, placing it in the top 92.9%.
Is Sci Pharmtech's EV-to-EBIT too high?
Sci Pharmtech's current EV-to-EBIT of 86.45 is 418% above median its 10-year median of 16.68. The Drug Manufacturers industry median EV-to-EBIT is 15.12. Sci Pharmtech's value of 86.45 is 471.9% above this industry median. Based on the distribution chart, Sci Pharmtech ranks #641 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sci Pharmtech has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sci Pharmtech ranks #641 out of 690 companies for EV-to-EBIT. This places Sci Pharmtech in the lower half of its industry. The industry median EV-to-EBIT is 15.12. Sci Pharmtech's value of 86.45 is 471.9% above this benchmark. While the company's 10-year median is 16.68 vs. the industry median of 15.12, Sci Pharmtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.12, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sci Pharmtech's current EV-to-EBIT of 86.45 is 471.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sci Pharmtech and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sci Pharmtech's current EV-to-EBIT is 86.45, which is 418% above median its own 10-year median of 16.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Possible Value Trap. The stock's GF Value™ is NT$74.27, compared to a current price of NT$52.30 — trading 29.6% below its estimated fair value. The current EV-to-EBIT is 86.45, which is 418% above median its 10-year median of 16.68 and 471.9% above the Drug Manufacturers industry median of 15.12. Sci Pharmtech's overall GF Score™ is 75/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current EV-to-EBIT is 86.45 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sci Pharmtech (TPE:4119) Overvalued in 2026?
Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued.
The current stock price of NT$52.30 is trading 29.6% below its estimated GF Value™ of NT$74.27.
GuruFocus considers Sci Pharmtech to be Possible Value Trap.
Key valuation signals for TPE:4119:
EV-to-EBIT: 86.45 (418% above median its 10-year median of 16.68)
GF Value™: NT$74.27 vs. price of NT$52.30 (29.6% below fair value)
Industry Position: 471.9% above the Drug Manufacturers median (#641 of 690)
No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
75GF Score
Get the complete analysis for TPE:4119
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4119 has been successfully added to your 
